JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

Search

Minerva Neurosciences Inc

Open

1.88 -6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.81

Max

2.01

Schlüsselkennzahlen

By Trading Economics

KGV

Branchendurchschnitt

2.197

38.156

EPS

-0.5

Angestellte

8

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.6M

11M

Vorheriger Eröffnungskurs

7.88

Vorheriger Schlusskurs

1.88

Minerva Neurosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Juli 2025, 23:57 UTC

Akquisitionen, Fusionen, Übernahmen

EQT: To Spend Y407.82B for Tender Offer

29. Juli 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

EQT: Tender Offer Price Is Y5,700 a Share

29. Juli 2025, 23:54 UTC

Akquisitionen, Fusionen, Übernahmen

EQT To Start Tender Offer for Fujitec

29. Juli 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29. Juli 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29. Juli 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29. Juli 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29. Juli 2025, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29. Juli 2025, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29. Juli 2025, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29. Juli 2025, 22:35 UTC

Ergebnisse

IGO Maintains Nova Life of Mine Production Guidance

29. Juli 2025, 22:35 UTC

Ergebnisse

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29. Juli 2025, 22:35 UTC

Ergebnisse

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29. Juli 2025, 22:34 UTC

Ergebnisse

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29. Juli 2025, 22:34 UTC

Ergebnisse

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29. Juli 2025, 22:34 UTC

Market Talk
Ergebnisse

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29. Juli 2025, 22:33 UTC

Ergebnisse

IGO Had A$279.7 Million of Cash at End-June

29. Juli 2025, 22:33 UTC

Ergebnisse

IGO 4Q Underlying Free Cash A$2.4 Million

29. Juli 2025, 22:33 UTC

Ergebnisse

IGO FY Sales Revenue A$512.5 Million

29. Juli 2025, 22:33 UTC

Ergebnisse

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29. Juli 2025, 22:32 UTC

Ergebnisse

IGO FY Nickel Production 17,173 Tons

29. Juli 2025, 22:32 UTC

Ergebnisse

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29. Juli 2025, 22:32 UTC

Ergebnisse

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29. Juli 2025, 22:31 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

29. Juli 2025, 22:31 UTC

Market Talk
Ergebnisse

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29. Juli 2025, 22:31 UTC

Ergebnisse

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29. Juli 2025, 22:31 UTC

Ergebnisse

IGO FY Spodumene Production 1.48 Million Tons

29. Juli 2025, 22:30 UTC

Ergebnisse

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29. Juli 2025, 22:30 UTC

Ergebnisse

IGO 4Q Underlying Ebitda A$62 Million

29. Juli 2025, 22:22 UTC

Ergebnisse

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer-Vergleich

Kursveränderung

Minerva Neurosciences Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Finanzen

$

Über Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.